Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  Ablynx    ABLX   BE0003877942

ABLYNX (ABLX)
My previous session
Most popular
  Report  
SummaryQuotesNewsCalendarCompanyFinancialsRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Ablynx : 07/09/2017 ABLYNX TO PRESENT AT UPCOMING INVESTOR CONFERENCES IN LONDON

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/07/2017 | 09:43am CEST
ABLYNX TO PRESENT AT UPCOMING INVESTOR CONFERENCES IN LONDON GHENT, Belgium, 7 September 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announces that it will participate in the following upcoming investor conferences taking place in London, UK:
  • J.P. Morgan's London Small/Mid Cap Conference: one-on-one meetings with institutional investors are scheduled for Thursday 14 September 2017.
  • Bank of America Merrill Lynch (BAML) Global Healthcare Conference: a presentation is scheduled for Friday 15 September 2017 at 01.45 p.m. GMT (02.45 p.m. Central European Time), followed by a breakout session, together with one-on-one meetings with institutional investors. The slides will be available, shortly after the presentation is given, on the Company's website, under the News & Events section.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

For more information, please contact: Ablynx

Dr Edwin Moses CEO

t: +32 (0)9 262 00 07

m: +32 (0)473 39 50 68

e: [email protected]

Lies Vanneste Director IR

t: +32 (0)9 262 0137

m: +32 (0)498 05 35 79

e: [email protected]

@AblynxABLX

Ablynx media relations: Consilium Strategic Communications

Mary-Jane Elliott, Philippa Gardner, Sukaina Virji t: +44 (0)20 3709 5700

e: [email protected]

Disclaimer

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any an ticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be tak en as a representation that such trends or activities will continue in the future. As a result, the Company expressly dis claims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forwa rd-looking statements are based. Neither the Company nor its advisers or representatives nor any of its parent or subsidiary undertakings or any such p erson's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does eitheraccept any responsibility forthe future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Ablynx NV published this content on 07 September 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 07 September 2017 07:42:04 UTC.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABLYNX
07/10ACCELERON PHARMA : Appoints Robert K. Zeldin, M.D., Chief Medical Officer
AQ
07/06SANOFI : - CHMP recommends approval of Cablivi
AQ
06/30Sanofi, Advent finally shake hands on $2.2B European generics sale
AQ
06/29ABLYNX : `Rapidly evolving` biotech company to create 10 jobs at York Science Pa..
AQ
06/29SANOFI : CHMP Recommends Approval of Cablivi (Caplacizumab)
AQ
06/22SANOFI : completes its acquisition of Ablynx following the expiration of the Squ..
AQ
06/21SANOFI : completes $3.9bn acquisition of Ablynx
AQ
06/20SANOFI : Completes Its Acquisition of Ablynx Following Expiration of Squeeze-Out..
AQ
06/19ABLYNX : Sanofi completes its acquitision of ablynx following the expiration of ..
GL
05/29ABLYNX : Crossing thresholds
CO
More news
News from SeekingAlpha
05/02YOUR DAILY PHARMA SCOOP : KPTI Data, Allergan Write-Off, Celgene Down On Delay 
04/30Ablynx completes enrollment in mid-stage study of ALX-0171 in RSV 
03/26Ablynx's vobarilizumab flunks mid-stage lupus study 
03/02Mid-stage study underway in Japan for Ablynx ALX-0171 in RSV 
02/22Ablynx NV reports FY results 
Financials (€)
Sales 2018 94,0 M
EBIT 2018 -9,76 M
Net income 2018 -
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 37,2x
Capi. / Sales 2019 19,8x
Capitalization 3 498 M
Income Statement Evolution
Managers
NameTitle
Edwin Moses Chief Executive Officer & Executive Director
Russell G. Greig Chairman
Wim Ottevaere Chief Financial Officer
Robert Freisen Chief Scientific Officer
Remi Vermeiren Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ABLYNX117.28%0
CELLTRION, INC.--.--%32 245
IQVIA HOLDINGS INC13.49%22 746
LONZA GROUP8.32%21 355
INCYTE CORPORATION-26.93%14 861
SEATTLE GENETICS, INC.31.33%11 158